Objectives: Among woman, breast cancer is the most prevalent cancer worldwide. It is composed of various cell types that are classified into different subtypes such as triple negative breast cancer (TNBC), triple positive breast cancer (TPBC). TNBCs and TPBCs represent distinct genetic background, thereby leading to therapeutic diversity in breast cancer. It is critical to know their tumorigenic properties to overcome the diversity.
INTRODUCTION
Breast cancer is the first frequent cancer and remains also the second important matter of cancer death in women worldwide 1 . It has heterogeneity and is classified into Luminal A, Luminal B, human epidermal growth factor receptor type 2 (HER2) positive, triple positive breast cancer (TPBC) and triple negative (basal like) breast cancer (TNBC). Based on molecular and biological properties of the cancer, treatment protocol has designed with drugs targeting interested subtypes. Treatment response varies due to lack of targeted therapy or drug resistance 2, 3 .
The major problem in the resistance is the existence of cancer stem cells (CSCs), leading to treatment failure 4 . CSCs are a small subpopulation of neoplastic cells and capable of self-renewal, tumor progression and metastasis 5 . They drive a cellular hierarchy due to their differentiation ability which causes tumor cellular heterogeneity 6 . Therefore, a therapeutic approach could be a selective targeting of CSCs to manage tumor proliferation.
Iron is an essential nutrient that plays a role in functions of vital enzymes involved in DNA replication, cell cycle, cellular respiration, etc [7] [8] [9] .
Tumor cells need more iron than their normal counterparts to keep up with increased rates of cell growth 10 . Metabolic process and cellular proliferation could be reduced by iron depletion. This can be achieved by treatment of iron chelators like and di-2-pyridylketone 4, 4-dimethyl-3-thiosemicarbazone (Dp44mT), deferasirox, desferrioxamine (DFO) that are used in clinical applications for sequestering iron [11] [12] [13] . These compounds have been used as chemotherapeutic drugs for inhibition of cancer cell growth and of maintenance of CSCs 14 .
Although several studies have done to investigate impacts of iron depletion on breast CSCs (BCSCs), little is known about iron dependency of BCSCs 9, 15, 16 . In the current study, intracellular iron levels of breast cancer cell lines; MDA-MB-435, MDA-MB-231, Hs578T, BT474, HCC1954, were measured via a fluorescent probe, calcein-AM, utilizing flow cytometry. BCSCs are identified by surface expression of CD44+/CD24-markers in the lines. Effect of iron addition on the population of BCSCs in BT474 and HCC1954 cells was also determined by flow cytometry.
METHODS

Cell Culture
MDA-MB-435, Hs578T, MDA-MB-231, BT474 and HCC1954 cell lines were supplied from the American Type Culture Collection (ATCC, Manassas, VA, USA). Dulbecco's modified Eagle's medium (DMEM), added to 10% (v/v) fetal bovine serum (FBS; Thermo Fisher Scientific) and 1% penicillin/streptomycin solution (Invitrogen, Gaithersburg, MD, USA), was used to culture MDA-MB-435, Hs578T and MDA-MB-231 cells. BT474 and HCC1954 cells were cultured in RPMI with 10% FBS and 1% penicillin/streptomycin solution. All cell lines were cultured in 5% CO2 humidification and in 10 cm2 dishes (New York, USA) at 37°C. When grown 75-85% of the dish, cells were replated after digesting them with trypsin (trypsinethylenediaminetetraacetic acid (EDTA), Invitrogen) for each 4 days.
Flow Cytometry for BCSCs
BCSCs were identified by utilizing expression of surface markers (CD44, CD24). Analysis was done with antibodies-anti-CD44-FITC and anti-CD24-PE (BD Biosciences, Franklin Lakes, NJ, USA). Cells were suspended in the buffer (PBS including 0.1% FBS), set to 1×106 cells per tube, following treatment of trypsin. For CD44/CD24 assay, antibodies were supplemented to the suspension according to the manufacturer recommendations. Incubation was done without light on ice for 30 min. Iron was exogenously added to the medium as previously done 15 . BD Accuri C6 (Becton Dickinson, San Josè, CA, USA) device was used to run samples and analysis was done with the manufacturers' software. CD44+/CD24-cells on histograms reflects BCSC population.
Flow Cytometry for Iron Detection
Cells were harvested in trypsin treatment and washed twice with PBS. Staining was applied in serum-free medium including 0.5 μMcalcein-AM (C-AM, Sigma, St. Louis, MO, USA) and cells were incubated for 30 min in dark at 37°C. They were washed and suspended in the buffer. Samples were run with BD Accuri C6. For each sample, mean fluorescence was measured and analysis was done using BD's program. Intracellular iron levels were inversely correlated with calcein-AM fluorescence shown in the form of mean fluorescence. The lowest fluorescence, meaning highest iron level, was set as 1 and fold-change was calculated in other cell lines.
Statistical Analysis
Results are shown as the mean ± SEM. Statistical significance was considered on p values (≤ 0.05) calculated by a paired two-sided Student's t test.
RESULTS
Basal Iron Levels of Breast Cancer Cell Lines
In order to determine basal iron levels in these cell lines, intracellular iron levels were measured comparatively. MDA-MB-435 cells have the highest iron levels compared to other cells. TNBC cells have higher basal iron levels than TPBC cells (Figure 1) .
Comparison of BCSCs Populations
To determine population of BCSCs in breast cancer cell lines, cells were grown for 5 days and expression of CD44+/CD24-markers were detected. TNBC cell lines represented very high levels, more than 90%, of BCSC expression, however; it was quite low, less than 2%, in TPBCs compared to TNBCs (Figure 2) .
Enrichment of BCSCs via Iron Addition
TPBC cell lines, BT474 and HCC1954, were treated with 20 µM FeCl3 for 5 days to examine iron-mediated alteration in population of BCSCs. In both cell lines, iron supplement increased BCSC population more than 2-fold ( Figure 3) . 
DISCUSSION
Breast cancer heterogeneity is very high and the modelling which comprises a panel of genetically and epigenetically distinct diseases with different phenotypical associations has been widely performed utilizing breast cancer cell lines [17] [18] [19] [20] . MDA-MB-435, MDA-MB-231 and Hs578T cell lines are known as TNBC cells; estrogen receptor (ER)-progesterone receptor (PR)-HER2-while BT474 and HCC1954 are TPBC cells; ER+PR+HER2+ 20 . As seen in Figure  1 , TNBC cells have higher basal iron levels than TPBC cells and MDA-MB-435 cells have the highest levels. TNBC cells grow fortissimo and are disposed to be more aggressive than other types of breast cancer such as TPBC 21 . To compensate for aggressive proliferation requirements, they need respectively elevated levels of intracellular iron. Findings are consistent with this phenomenon. CSCs are subpopulation of tumor cells that grows slowly and have the ability to promote tumorigenesis and metastasis 5, 22, 23 . CSC phenotype may be characterized by markers of iron-containing proteins. In a recent study, Chekhun et al. found that breast cancer cells exhibiting high degree of malignancy, labeled by the expression of CSC, show the greatest difference in the expression of main proteins of iron metabolism including transferrin, ferritin, ferroportin, hepcidin 24 . Hamai et al. showed that sequestered lysosomal iron by salimomycin and iromycin elevated irondepletion response resulting in iron-induced lysosomal generation of reactive oxygen species (ROS) followed by the death of CSCs 25 . Conventional cancer therapies aim at proliferating neoplastic cells and fail to kill CSCs 26 . Therefore, brightening what CSCs need to maintain their population provides new goals to improve the therapy efficacy. In present study, populations of BCSCs were determined in the cell lines and they were much higher in TNBC cell lines than those of TPBCs as seen in Figure 2 . These results were correlated to the iron content of the cell lines. The more a cell line represents intracellular iron and maintenance of BCSCs, the more chance it has to proliferate aggressively.
There are several studies that have purposed to identify drugs targeting CSCs specifically. Marx et al. found compounds that are able to silence selectively ErbB2 transcription in HER2-positive breast cancer cell lines 27 . In another study, Sun et al. identified potential inhibitors of survivin, a tumor antigen related to CSCs [28] . CD44+/CD24-subpopulation of BCSCs was significantly inhibited by salinomycin in a study done by Gupta et al. 29 . It was found that Dasatinib particularly inhibited growth of epithelial-mesenchymal transition (EMT)-stem cell-like cells in TNBCs 30 . In a recent study, researchers reported that benztropinemesylate inhibited population of BCSCs in vitro and in vivo 31 . These studies have shown selective targeting of CSCs to present promise for novel compounds of cancer therapeutics.
Cancer cells require iron for a number of functions involving proliferation, migration, invasion and metastasis [32] [33] [34] .Iron depletion by iron chelators-DFO, deferasirox inhibits the expression of stemness markers on CSCs, indicating significance of iron on the maintenance of stemness 15, 35 . In a recent study, researchers have shown that iron chelators repress proliferation of mouse induced pluripotent stem cells growing in Lewis lung carcinoma conditioned medium (miPS-LLCcm) and the expression of stemness markers-Nanog, SOX2, c-Myc, Oct3/7, Klf4 35 . It appears that iron is critical for the proliferation and survival of CSCs. In another recent study, Raggi et al. reported that DFO diminishes 3D stem-like tumorspheres forming efficiency, the expression of CSC markers and stem-like genes 36 .
Beside these findings, determining cellular requirements of CSCs may provide new targets for the therapy. In current study, it has been shown that there is a link between cellular iron levels and CD44+/CD24-subpopulation of BCSCs in the lines. Basal iron levels in TPBCs are enough to supply iron necessity for cell proliferation, however; they are not growing aggressively like TNBCs. Additionally, they are not generating tumor quickly and highly invasive compared to TNBCs 20 . This is why TNBCs demonstrate very high levels of BCSCs. It is obvious that tumorigenesis may be enhanced by the supplement of vital nutrients like iron or by presence of high levels of CSCs. Targeting essential genes regulating iron homeostasis or controlling the maintenance of CSCs might be a significant approach to prevent breast cancer.
